UNIQURE N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.33 USD | +0.38% |
|
+7.68% | -21.27% |
| Jun. 03 | UniQure Shares Rise After US FDA Grants Regenerative Medicine Advanced Designation for Huntington's Treatment | MT |
| Jun. 03 | UniQure's AMT-130 Gets FDA RMAT Designation in Huntington's Disease | DJ |
| Sales 2024 * | 49.47M 53.42M | Sales 2025 * | 87.7M 94.72M | Capitalization | 239M 259M |
|---|---|---|---|---|---|
| Net income 2024 * | -218M -235M | Net income 2025 * | -167M -180M | EV / Sales 2024 * | 3.44 x |
| Net cash position 2024 * | 69.35M 74.9M | Net Debt 2025 * | 9.03M 9.75M | EV / Sales 2025 * | 2.83 x |
| P/E ratio 2024 * |
-1.16
x | P/E ratio 2025 * |
-1.46
x | Employees | 480 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.72% |
More Fundamentals
* Assessed data
More news
Latest transcript on uniQure N.V.
More recommendations
More press releases
| 1 day | +0.38% | ||
| 1 week | +7.68% | ||
| Current month | +7.68% | ||
| 1 month | +10.58% | ||
| 3 months | +0.95% | ||
| 6 months | -26.99% | ||
| Current year | -21.27% |
1 week
5.07
5.62
1 month
4.525.62
Current year
4.257.12
1 year
4.2520.84
3 years
4.2538.80
5 years
4.2582.49
10 years
4.2582.49
| Managers | Title | Age | Since |
|---|---|---|---|
Matt Kapusta
CEO | Chief Executive Officer | 51 | 14-12-31 |
Christian Klemt
DFI | Director of Finance/CFO | 51 | 14-12-31 |
Pierre Caloz
COO | Chief Operating Officer | 52 | 21-05-16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leonard Post
BRD | Director/Board Member | 72 | 20-06-16 |
Jack Kaye
BRD | Director/Board Member | 80 | 16-06-14 |
| Director/Board Member | 61 | 17-09-13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.96% | 11 M€ | -6.03% | - | |
| 0.76% | 15 M€ | -3.61% | ||
| 0.48% | 28 M€ | -3.53% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 5.33 | +0.38% | 451,369 |
| 24-06-06 | 5.31 | -2.21% | 324,131 |
| 24-06-05 | 5.43 | +0.18% | 1,021,561 |
| 24-06-04 | 5.42 | +1.69% | 1,019,953 |
| 24-06-03 | 5.33 | +7.68% | 1,916,688 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotes
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Companyâs lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntingtonâs disease is in Phase I/II clinical study.
Calendar
2024-06-18
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
4.931
EUR
Average target price
17.06
EUR
Spread / Average Target
+245.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.27% | 259M | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +3.23% | 22.78B | |
| -10.44% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- QURE Stock
